Michael Benkowitz Sells 14,440 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 14,440 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $472.13, for a total transaction of $6,817,557.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 9th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $474.65, for a total transaction of $10,679,625.00.
• On Monday, February 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.95, for a total transaction of $10,596,375.00.
• On Tuesday, January 20th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total value of $6,795,652.50.
• On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total value of $3,659,197.50.
• On Monday, January 26th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $471.91, for a total value of $10,617,975.00.
• On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.51, for a total value of $10,788,975.00.
• On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $487.38, for a total value of $3,838,117.50.
• On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $7,127,932.50.
• On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $502.79, for a total transaction of $11,312,775.00.
• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $514.35, for a total transaction of $11,572,875.00.

United Therapeutics Trading Up 13.0%

NASDAQ UTHR opened at $535.10 on Thursday. The company has a fifty day simple moving average of $484.71 and a two-hundred day simple moving average of $444.09. The stock has a market cap of $23.04 billion, a P/E ratio of 20.28, a P/E/G ratio of 2.52 and a beta of 0.85. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $537.19.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company earned $6.19 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Wells Fargo & Company upped their target price on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Wednesday. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. HC Wainwright boosted their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Finally, Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a research report on Wednesday. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 earnings beat consensus — UTHR reported $7.70 EPS vs. a $6.78 consensus, showing solid margin expansion and year‑over‑year EPS growth, which supports valuation and drove buying interest. United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates
• Positive Sentiment: Record full‑year revenue — company reported record 2025 revenue of $3.18B (up ~11% y/y), reinforcing longer‑term growth narrative beyond the quarter. Business Wire: United Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Unusual call option activity — heavy buy interest in calls (several thousand contracts) suggests some traders are positioning for further upside or event‑driven moves, which can amplify intraday gains.
• Neutral Sentiment: Analysts mixed but not uniformly negative — Morgan Stanley kept a Hold with a $447 target, while other firms maintain buy ratings and higher targets; consensus remains a modest “Moderate Buy,” leaving room for divergent investor views. Balanced Hold on United Therapeutics Amid Near‑Term Pressure
• Negative Sentiment: Revenue missed estimates — quarterly revenue of $790.2M fell short of the ~$814.8M consensus, which pressured the stock earlier and explains conflicting headlines about an earnings beat vs. a revenue miss. United Therapeutics stock falls nearly 5% on revenue miss despite earnings beat
• Negative Sentiment: Significant insider selling — recent large sales by COO Michael Benkowitz (multiple blocks including 14,440 shares) and a director (Christopher Causey) add selling pressure and raise governance/near‑term sentiment concerns. COO Michael Benkowitz Sells Shares Director Christopher Causey Sells Shares

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the business. Torren Management LLC purchased a new position in United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the period. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new stake in United Therapeutics in the 4th quarter valued at $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.